DHR
Danaher Corp /De/Price & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP adjusted diluted net earnings per common share non-GAAP | $2.06 | Q1 2026 | — |
| Non-GAAP core revenue growth non-GAAP | 0.5% | Q1 2026 | — |
|
|
|||
| Non-GAAP free cash flow non-GAAP | $1.1B | Q1 2026 | — |
|
|
|||
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DHR
this stock
Danaher Corp /De/
|
$138.71B | -12.7% | +8.5% | 37.8 | 1.5% |
|
TMO
Thermo Fisher Scientific Inc.
|
$195.86B | -9.0% | +0.4% | 29.0 | 1.4% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.46B | -16.7% | +10.4% | 41.5 | 2.5% |
|
NTRA
Natera, Inc.
|
$38.66B | +17.8% | -2.8% | — | 4.1% |
|
A
Agilent Technologies, Inc.
|
$37.93B | -0.9% | +6.4% | 27.0 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DHR | +0.6% | +8.6% | -16.7% | +4.5% | -12.7% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -0.8% | +4.6% | -25.7% | +3.4% | -23.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.